Back to results
US 2019/0167665 A1Published application
Morphine formulations
AssigneeFresenius Kabi Deutschland GmbH
InventorsAlain CUINE, Didier HOARAU, Pauline ROMAIN
Life of this patent
Estimating the term…
Abstract
Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
Claims21
1-49. (canceled)
A pharmaceutical formulation comprising:
- (a) morphine, or a salt thereof, or a hydrate thereof;
- (b) an isotonic agent;
- (c) a buffering agent with anti-oxidative properties;
- (d) a chelating agent;
- (e) a complement to a chelating agent;
- and
- (f) water,
- wherein the formulation has a pH of from about 2.5 to about 6.5.
5 more elements
A pharmaceutical formulation comprising:
- (a) morphine, or a salt thereof, or a hydrate thereof;
- (b) an isotonic agent;
- (c) a buffering agent with anti-oxidative properties;
- (d) a chelating agent;
- (e) a complement to a chelating agent;
- and
- (f) water,
- wherein the formulation comprises no more than about 1.5% total impurities following storage at 25° C. and 60% Relative Humidity for at least 12 months.
5 more elements
A pharmaceutical formulation comprising:
- (a) morphine, or a salt thereof, or a hydrate thereof;
- (b) an isotonic agent;
- (c) a buffering agent with anti-oxidative properties;
- (d) a chelating agent;
- (e) a complement to a chelating agent;
- and
- water,
- wherein the formulation comprises no more than about 0.2% pseudomorphine following storage at 25° C. and 60% Relative Humidity for at least 12 months.
5 more elements
Dependencies are inferred from the claim text.